Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China
Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)
DOI: 10.57264/cer-2026-0146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Genyong Zuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Management & Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, C…. Hauptthemen laut MEDLINE: Multiple Myeloma, Boron Compounds, Glycine, Antibodies, Monoclonal. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Aim
Expanding treatment options for transplant-ineligible newly diagnosed multiple myeloma (ndMM) in China has increased the need to identify treatment strategies that improve patient outcomes while using healthcare resources efficiently. This study evaluated the cost-effectiveness of in-class transition (iCT) to ixazomib, lenalidomide and dexamethasone (IRd) versus daratumumab, lenalidomide and dexamethasone (DRd) for transplant-ineligible ndMM from the perspective of the Chinese healthcare system. Materials & methods: A cost-effectiveness analysis was conducted using a Markov cohort model that simulated lifetime health benefits and medical costs for the two treatment modalities. Model inputs were estimated from best available real-world evidence in the literature and from public data sources. Deterministic, probabilistic and scenario sensitivity analyses were performed to assess uncertainty in model results.
Results
In the base-case analysis, iCT IRd was projected to generate 0.580 additional quality-adjusted life years versus DRd (4.724 vs 4.144) and save lifetime medical costs by $7751. One-way sensitivity analysis indicated that cost-effectiveness was driven by uncertainty in model inputs related to treatment discontinuation and subsequent disease progression. Probabilistic sensitivity analysis estimated that iCT IRd had 79.2%, 88.0% and 91.3% probabilities of being cost-effective at willingness-to-pay thresholds of one, two and three-times China’s 2025 gross domestic product per capita per quality-adjusted life year, respectively.
Conclusion
Based on best available real-world evidence, the iCT IRd modality could be cost-effective compared with the DRd modality for transplant-ineligible patients with ndMM in China. Future real-world studies are needed to confirm the projected outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Health Management & Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
- NHC Key Lab of Health Economics & Policy Research, Shandong University, Jinan, Shandong, 250012, China.
- Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, 100020, China.
- School of Clinical Medicine, Zhengzhou University, Zhengzhou, Henan, 450000, China.
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, Henan, 450000, China.
- Department of Hematology, Beijing Jishuitan Hospital, Beijing, 100096, China.
ORCID-Profile: Genyong Zuo, Wendong Chen, Rong Fu, Wenming Chen
Zitieren
APA
Zuo, G., Liu, A., Zhu, Z., Bao, L., Liu, L., Gao, Y., Chen, W., Fu, R., & Chen, W. (2026). Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0146
Vancouver
Zuo G, Liu A, Zhu Z, Bao L, Liu L, Gao Y, et al. Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0146
BibTeX
@article{Zuo2026,
author = {Zuo, Genyong and Liu, Aijun and Zhu, Zunmin and Bao, Li and Liu, Lihong and Gao, Yongbo and Chen, Wendong and Fu, Rong and Chen, Wenming},
title = {Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {11},
doi = {10.57264/cer-2026-0146}
}
EUVIMED